2020
Presentation for SACHS 3rd Neuroscience Innovation Forum
ANP to Present at Neuroscience Innovation Forum in the US
2019
Change of Directors Interest Notice (RM, MD, GM, GP, WG)
Change of Directors Interest Notice (WG)
Change of Directors Interest Notice (RM)
Change of Directors Interest Notice (RM)
Change of Directors Interest Notice (MD)
Change of Directors Interest Notice (GM)
Positive Results reaffirm plans to advance ATL1102 to Phase IIb
Underwriting of Listed Options
Change of Directors Interest Notice (RM)
AGM Presentation December 2019
Change of Directors Interest Notice (RM)
Dosing Completed in ATL1102 Phase II DMD trial
Additional ATL1102 trial data presented at DMD UK conference
Antisense Therapeutics Listed Option Exercise
Notice of Annual General Meeting/Proxy Form incl. Annual Report
ANP – Appendix 3B – 29 Oct 2019
Neuromuscular Drug Development Summit Poster Presentation
ANP – Appendix 4C – 30 Sept 19_final
ANP to present at Neuromuscular Drug Development Summit in USA
ANP – Appendix 3B – 04 Oct 2019
Positive Preliminary results from ATL1102 for DMD Phase II trial
ATL1102 for DMD commencement of European regulatory interactions
ATL1102 Phase II clinical trial in DMD update
Conference Presentation June 2019
ATL1102 Phase II clinical trial in DMD final enrolment
ATL1102 Phase II clinical trial in DMD update
Placement to Accelerate Development of ATL1102 in DMD
ASX 19_30 Jan_ANP – Appendix 4C – 31 Dec 18
ASX 19_23 Jan_Updated Company Presentation
ASX 19_ 18 January ATL1102 Phase II clinical trial in DMD update_Final
2018
View the 2018 announcements on the ASX website
2017
View the 2017 announcements on the ASX website
